Olema Pharmaceuticals, Inc. Stock Price, News & Analysis

Olema Pharmaceuticals (OLMA) announced the completion of the dose-escalation stage in its Phase 1/2 clinical trial for OP-1250, targeting metastatic, ER+/HER2- breast cancer. Interim data will be presented at the 2021 San Antonio Breast Cancer Symposium. The company plans to initiate a Phase 2 study and a Phase 1b trial with a CDK4/6 inhibitor in early 2022. Financially, Olema reported a Q3 net loss of $17.7 million, up from $7.8 million in 2020, with R&D expenses reaching $12.5 million, reflecting ongoing trial costs. Cash reserves total $306 million, sufficient until late 2023.

Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on women's cancers, announced participation in two investor conferences this November. The events include the Jefferies London Healthcare Conference on November 16, 2021, at 5:00 p.m. GMT, and the 4th Annual Evercore ISI HealthCONx Conference on November 30, 2021, at 11:45 a.m. ET. Live webcasts will be available on Olema’s website and archived for 14 days. Olema’s lead product, OP-1250, targets ER-positive breast cancer and is currently undergoing clinical trials.

Olema Pharmaceuticals (Nasdaq: OLMA) announced a poster presentation on OP-1250, a dual action therapy for metastatic breast cancer, at the virtual AACR-NCI-EORTC Conference from October 7-10, 2021. The presentation will detail an ongoing Phase 1/2 study of OP-1250, a complete estrogen receptor antagonist and selective degrader, targeting ER-positive, HER2-negative breast cancer. Preliminary data from the trial's dose escalation phase is expected in Q4 2021. Olema focuses on women's cancers, with OP-1250 as its leading candidate.

Olema Pharmaceuticals (Nasdaq: OLMA) announced a poster presentation featuring preclinical data on OP-1250, a complete estrogen receptor antagonist and selective ER degrader. This data will be showcased at the 1st JCA-AACR Precision Cancer Medicine International Conference, occurring virtually from September 10-12, 2021. The presentation, titled "Complete Estrogen Receptor (ER) Antagonism As An Optimal Approach for ER-Positive Breast Cancer Drug Development," will be available on-demand on the conference website. The company aims to advance targeted therapies for women’s cancers.

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on targeted therapies for women's cancers, announced that Sean P. Bohen, M.D., Ph.D., CEO, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 4:15 p.m. ET. A live webcast will be available on Olema's website and archived for 14 days.

Olema’s lead candidate, OP-1250, is currently under evaluation for its effectiveness in treating ER-positive, HER2-negative breast cancer in a Phase 1/2 clinical trial.

Olema Pharmaceuticals reported significant advancements in its clinical trial for OP-1250, an investigational complete estrogen receptor antagonist, focusing on metastatic ER+/HER2- breast cancer. As of June 30, 2021, Olema holds $318.1 million in cash, expected to fund operations through 2023. The second quarter saw a net loss of $16.4 million, driven by increased R&D and G&A expenses, up from $1.9 million and $0.5 million, respectively, in the previous year. Importantly, 28 patients were enrolled in the Phase 1/2 trial, with interim data presentation anticipated in Q4 2021.

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on women’s cancers, announced that its CEO, Sean P. Bohen, will present at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 3:00 p.m. ET. The presentation will be accessible via live webcast on Olema’s website, which will be archived for 14 days. Olema's lead candidate, OP-1250, is being evaluated in a Phase 1/2 trial for ER-positive, HER2-negative breast cancer.

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on women’s cancers, announced that CEO Sean P. Bohen will participate in a virtual fireside chat at the Jefferies 2021 Virtual Healthcare Conference on June 1, 2021, at 4:30 p.m. ET. The webcast will be available on Olema's website and archived for 14 days. Olema's lead candidate, OP-1250, is currently in a Phase 1/2 trial for ER-positive, HER2-negative breast cancer.

Olema Pharmaceuticals (Nasdaq: OLMA) reported progress in its Phase 1/2 trial of OP-1250 for ER+/HER2- breast cancer, with initial data expected in late 2021. The company holds $327 million in cash as of March 31, 2021, sufficient to fund operations through 2023. Q1 net loss was $15.3 million, up from $1.7 million year-over-year, with R&D expenses at $10.7 million due to heightened development activities. Olema appointed Yi Larson to its Board and strengthened R&D capabilities with new lab facilities in San Francisco.